WAVE Life Sciences Ltd (NASDAQ:WVE) is set to release its Q3 2024 earnings on Nov 12, 2024. The consensus estimate for Q3 ...

The past four years have brought disappointment for the Huntington’s community, but optimism is growing as companies ...

Wave Life Sciences (NASDAQ:WVE – Get Free Report) had its price objective increased by research analysts at B. Riley from $19.00 to $22.00 in a note issued to investors on Monday, Benzinga reports.

According to a post on the FDA’s website, Wave Life Sciences (WVE)’ treatment of Huntington’s disease received orphan ...

For the most recent quarter, Wave Life Sciences reported -$0.25 earnings per share (EPS), missing the consensus estimate of ...

Wall Street expects a year-over-year decline in earnings on lower revenues when Wave Life Sciences (WVE) reports results for the quarter ended September 2024. While this widely-known consensus outlook ...

B. Riley raised the firm’s price target on Wave Life Sciences (WVE) to $22 from $19 and keeps a Buy rating on the shares following the ...

WVE-007 (INHBE GalNAc-siRNA for obesity) is on track to initiate a clinical trial in 1Q 2025; new preclinical data for ...

Wave Life Sciences (NASDAQ:WVE – Get Free Report) had its price objective upped by Leerink Partners from $20.00 to $22.00 in a note issued to investors on Wednesday, Benzinga reports.

Wave Life Sciences Ltd. (NASDAQ: WVE) is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health. The company is generating ...